Encefalopatía y neuromielitis óptica: importancia del reconocimiento de la sintomatología atípica

Hervás García, José V; Grau López, Laia; Doménech Puigcerver, Sira; Ramo Tello, Cristina.
Rev. neurol. (Ed. impr.) ; 58(1): 20-24, 1 ene., 2014. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-117852

Documentos relacionados

  1. Anti-Argonaute antibodies as a potential biomarker in NMOSD.
  2. Research and progress on biomarkers of neuromyelitis optica spectrum disorders.
  3. Analysis of site-specific glycan profiles of serum proteins in patients with multiple sclerosis or neuromyelitis optica spectrum disorder-a pilot study.
  4. Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?
  5. Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein.
  6. Treatment of Neuromyelitis Optica Spectrum Disorders.
  7. A Rare Variant of Neuromyelitis Optica.
  8. [Neuromyelitis optica spectrum: novel concept of pathogenesis, diagnosis and treatment of Devic's disease].
  9. [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].
  10. Espectro de neuromielitis óptica: ¿seropositivo para la anticuaporina es una entidad diferente de los pacientes que son seronegativos? Una perspectiva de Colombia